Grifols (NASDAQ:GRFS) Price Target Increased to €9.00 by Analysts at Barclays

Grifols (NASDAQ:GRFSGet Rating) had its target price hoisted by Barclays from €8.00 ($8.16) to €9.00 ($9.18) in a research report released on Monday morning, The Fly reports.

GRFS has been the subject of a number of other reports. Morgan Stanley lowered their price target on shares of Grifols from €20.00 ($20.41) to €13.00 ($13.27) in a report on Monday, October 10th. Jefferies Financial Group initiated coverage on Grifols in a research note on Monday, July 25th. They issued a hold rating on the stock. JPMorgan Chase & Co. lowered their price target on Grifols from €11.50 ($11.73) to €10.30 ($10.51) in a research report on Wednesday, September 14th. StockNews.com started coverage on Grifols in a report on Wednesday, October 12th. They issued a hold rating for the company. Finally, Deutsche Bank Aktiengesellschaft reduced their target price on Grifols from €16.00 ($16.33) to €10.00 ($10.20) and set a hold rating on the stock in a research note on Tuesday, October 25th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of Hold and an average price target of $12.52.

Grifols Stock Up 3.1 %

GRFS opened at $8.23 on Monday. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.91 and a current ratio of 2.68. Grifols has a 1 year low of $5.71 and a 1 year high of $13.34. The stock’s 50 day simple moving average is $6.91 and its 200 day simple moving average is $9.30.

Institutional Trading of Grifols

Several large investors have recently bought and sold shares of the company. Captrust Financial Advisors lifted its stake in shares of Grifols by 153.5% in the 2nd quarter. Captrust Financial Advisors now owns 2,086 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 1,263 shares during the period. Advisor Group Holdings Inc. lifted its position in Grifols by 16.3% during the first quarter. Advisor Group Holdings Inc. now owns 11,574 shares of the biotechnology company’s stock valued at $135,000 after buying an additional 1,619 shares during the period. Creative Planning lifted its position in Grifols by 15.7% during the third quarter. Creative Planning now owns 12,672 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 1,719 shares during the period. Cardinal Capital Management boosted its holdings in shares of Grifols by 3.9% during the 2nd quarter. Cardinal Capital Management now owns 57,615 shares of the biotechnology company’s stock valued at $684,000 after buying an additional 2,172 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its position in shares of Grifols by 40.0% in the 1st quarter. PNC Financial Services Group Inc. now owns 10,530 shares of the biotechnology company’s stock worth $122,000 after buying an additional 3,010 shares during the period. 14.62% of the stock is owned by institutional investors.

About Grifols

(Get Rating)

Grifols, SA engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases.

Read More

The Fly logo

Analyst Recommendations for Grifols (NASDAQ:GRFS)

Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.